Table 1. Patient Characteristics.
| Age/Gender | CD Duration(years) | BMI (Diagnosis) | BMI (Biopsy) | DM | HTN | Current Medications | TNF-a† | MTX† | AZA/6-MP† | Max AST | Max ALT | Biopsy‡ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 M | 10 | --- | 31.8 | No | Yes | Natalizumab | 2 yr | No | Yes | 88 | 207 | Grade 1, Stage 1 |
| 26 F | 13 | 22.9 | 35.3 | No | No | Adalimumab AZA | 1 yr | No | Yes | 75 | 96 | >75% Steatosis |
| 33 M | 13 | 24.3 | 36.5 | No | Yes | 6-MP | No | No | Yes | 99 | 195 | Grade 1, Stage 1 |
| 42 F | 10 | 35.6 | 39.3 | No | Yes | None | 2 yr | 3 yr | Yes | 53 | 72 | Grade 1, Stage 1 |
| 49 F | 17 | 21.8 | 24.2 | No | Yes | Adalimumab Prednisone | 4 yr | 3 yr | No | 57 | 52 | Grade 2, Stage 1 |
| 46 F | 6 | 27.9 | 33.5 | Yes | No | MTX | 1 yr | 1 yr | Yes | 105 | 127 | Grade 1, Stage 2-3 |
| 23 F | 13 | 21.7 | 26.36 | No | No | Adalimumab | 4 yr | 1.5 yr | Yes | 106 | 176 | Grade 1, Stage 1 |
All patients are Caucasian and carry the diagnosis of Crohn's disease. None of the patients carry a known diagnosis of hyperlipidemia.
All patients were previously treated with oral steroids with one patient receiving them currently.
BMI: Body Mass Index, DM: Diabetes Mellitus, HTN: Hypertension, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, MTX: Methotrexate, 6-MP: 6-Mercaptopurine, AZA: Azathioprine,, TNF-a: Tumor necrosis factor-alpha inhibitor
†
Duration of prior use
‡
Histologic classification according to Brunt criteria (Brunt EM, et al. Am J Gasroenterology 1999; 94:2467)